Details of Disease

General Information of Disease (ID: DISOF023)

Disease Name	Impetigo
Disease Class	1B72: Impetigo
Definition	A contagious bacterial cutaneous infection that affects children and is usually caused by Staphylococcus aureus. It usually presents in the face with honey colored scabs.
Disease Hierarchy	DIS04U9T: Streptococcus infection DISK6PTH: Staphylococcus aureus infection DISSRI0D: Skin disease caused by bacterial infection DISZ6M7Y: Pyoderma DIS3F9EY: Skin and skin-structure infection DISOF023: Impetigo
ICD Code	ICD-11 ICD-11: 1B72 ICD-10 ICD-10: L01, L01.0 ICD-9 ICD-9: 684 Expand ICD-11 '1B72 Expand ICD-10 'L01; 'L01.0 Expand ICD-9 684
Disease Identifiers	MONDO ID MONDO_0004592 MESH ID D007169 UMLS CUI C0021099 MedGen ID 9440 SNOMED CT ID 48277006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ozenoxacin	DM6KZMG	Approved	NA	[1]
Retapamulin	DM9JXB7	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
FMX102	DM7HLME	Phase 2	NA	[3]
TD-1414	DM9JMSA	Phase 2	NA	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GALNS	TTT9YPO	Strong	Biomarker	[5]
------------------------------------------------------------------------------------

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC9A6	DTN0JXW	Strong	Biomarker	[6]
------------------------------------------------------------------------------------

This Disease Is Related to 3 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
DSG1	OT11HC3A	Strong	Biomarker	[7]
PAGR1	OTXR5PQ8	Strong	Biomarker	[5]
SUMF2	OT37I8JL	Strong	Biomarker	[8]
------------------------------------------------------------------------------------

References

1	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022055.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT00758862) The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo. U.S. National Institutes of Health.
5	An antimicrobial role for zinc in innate immune defense against group A streptococcus.J Infect Dis. 2014 May 15;209(10):1500-8. doi: 10.1093/infdis/jiu053. Epub 2014 Jan 20.
6	Clonal change of methicillin-resistant Staphylococcus aureus isolated from patients with impetigo in Kagawa, Japan.J Dermatol. 2019 Apr;46(4):301-307. doi: 10.1111/1346-8138.14820. Epub 2019 Feb 25.
7	Production of recombinant extracellular domains of canine desmoglein 1 (Dsg1) by baculovirus expression.Vet Immunol Immunopathol. 2003 Oct 15;95(3-4):177-82. doi: 10.1016/s0165-2427(03)00107-7.
8	S. aureus PFGE patterns of lesional or non lesional strains from patients with impetigo: association of individual bands with lesional or non lesional areas.New Microbiol. 2000 Jan;23(1):29-36.